Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 150,364	$ 208,892
Short-term investments	68,138	50,441
Accounts receivable	25,116	22,934
Prepaid clinical development costs	698	1,138
Inventories, net	35,654	34,394
Other prepaid and current assets	10,849	11,173
Total current assets	290,819	328,972
Restricted cash	50,000	50,000
Property and equipment, net	511	664
Right of use operating lease assets	1,467	1,898
Intangible assets	56	56
Total assets	342,853	381,590
Current liabilities:
Accounts payable	26,829	17,559
Accrued clinical development costs	3,652	7,013
Other accrued liabilities	30,200	30,410
Revenue interest liability	13,392	11,295
Deferred revenue from collaborations	3,795	5,683
Operating lease liabilities	1,217	1,392
Total current liabilities	79,085	73,352
Convertible notes, net of issuance costs	258,678	258,280
Revenue interest liability	253,445	245,744
Operating lease liabilities	263	524
Deferred revenue from collaborations	422	634
Total liabilities	591,893	578,534
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March 31, 2022 and December 31, 2021	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 63,052,765 shares issued at March 31, 2022 and 62,873,694 shares issued at December 31, 2021	61	61
Additional paid-in capital	969,268	964,401
Treasury stock, at cost; 1,994,198 shares at March 31, 2022 and December 31, 2021	(54,998)	(54,998)
Accumulated other comprehensive loss	(263)	(31)
Accumulated deficit	(1,163,108)	(1,106,377)
Total stockholders’ deficit	(249,040)	(196,944)
Total liabilities and stockholders’ deficit	$ 342,853	$ 381,590